LynxCare, the Belgian clinical informatics company co-founded by Dr. Dries Hens, which transforms hospital data into real-world evidence for research, announces a capital increase welcoming Holland Capital as a new investor. Holland Capital, a Dutch investment firm with a strong track record in health tech, joins existing investors Elaia, HERAN Partners, b2venture and Matterwave Ventures, MTIP, and Vassoyan Conseil, who continue to back the company's growth.

Together with the appointment of Sue Beecroft as Chair of the Board, the investment marks the next phase for LynxCare: activating and scaling its European hospital network for multi-country research.
‍

Access to essential Real-World Data
‍

Traditional clinical trials test treatments in a strictly selected group of patients. Hospital records on the other hand show how those treatments perform in routine care, across a much broader and more diverse patient population in the real world.
‍

Yet much of that valuable clinical information - whether a tumour has progressed, how a patient responded to treatment, which side effects occurred - is written as free text in physician notes, pathology reports and discharge letters, not recorded in structured fields. LynxCare unlocks this information with its own small clinical language models. Unlike general-purpose AI, they are trained specifically on clinical text and extract detailed clinical information in an accurate and structured way. Because the models are compact, they can run efficiently on standard hospital infrastructure without sensitive clinical data leaving the hospital.  
‍

One standard across hospitals and countries
‍

The extracted data is converted into the OMOP Common Data Model, an international standard for observational health research. This allows the same real-world data (RWD) study to be run in the same way across different hospitals and countries.
‍

A federated network: patient data stays in the hospital
‍

Europe's hospital data is fragmented across countries, IT systems and governance rules. Centralising is slow and often not possible limiting the value and scale of real-world data studies in Europe.
‍

LynxCare's federated approach works the other way round. Data is structured and analysed at the source, inside each hospital, which keeps control over its use. Researchers and life sciences companies receive only the aggregated results, not patient-level records. This makes it possible to run observational studies across multiple hospitals and countries without first pooling sensitive data in one place.
‍

LynxCare takes a quality-first approach. Each dataset is systematically quality-checked and can be traced back to its source records. Clinical experts validate results, with their feedback continuously improving the models. The result is auditable data designed to meet the quality expectations of the European Health Data Space (EHDS).
‍

Growing European hospital network
‍

Over the past two years, LynxCare has grown strongly outside Belgium, with reference hospitals in France, Germany and Spain. The company has successfully delivered over a dozen real-world evidence (RWE) studies,  and contributed to more than 50 peer-reviewed scientific publications and abstracts. Recently, LynxCare has been selected as a finalist for the prestigious Prix Galien Bridges 2026, in the category Best Medical Technology/AI Advances in Human Health.
‍

The new funding will first be used to further activate and scale the existing network, and to increase capacity to deliver multi-country RWE studies. LynxCare will also continue to develop its clinical language models, with a strong focus on oncology, and pursue expansion into new European markets.
‍

"We are delighted to welcome Holland Capital as a new investor. Their experience in health tech is a strong endorsement of what we are building, and the continued commitment of our existing investors gives us a strong foundation for the next stage of growth," says Mikaela Bruhammar, CEO of LynxCare. "This funding will help us to continue bringing hospitals into our network and scale the evidence-generation projects we deliver with our life sciences partners."
‍

"What impressed me about LynxCare is the combination of deep medical understanding and proprietary clinical language models. In my view, this is key to unlocking hospital data across Europe for real-world insights," says Jan-Frens van Giessel, Partner at Holland Capital. "I’m excited to work with Mikaela and the team, bringing our healthcare experience and network to help them build lasting partnerships and grow across Europe."  
‍

Sue Beecroft joins as Chair of the Board
‍

Alongside the funding round, LynxCare welcomes Sue Beecroft as Chair of its Board of Directors.  Beecroft has more than 25 years of leadership experience in real-world evidence, healthcare data platforms and commercial strategy.  
‍

She founded Harvey Walsh and built it into a provider of healthcare data analytics and evidence-generation services for the pharmaceutical industry and the UK’s National Health Service (NHS), before its acquisition by OPEN Health in 2012. At OPEN Health she held senior leadership roles, as the company grew into an international business.
‍

Beecroft currently holds senior commercial and advisory roles at healthcare data companies, focusing on international data partnerships and federated real-world evidence networks. She also holds advisory and board roles with patient and clinical messaging networks. At LynxCare, she will focus on the company's commercial strategy and international partnerships as it moves from building its hospital network to scaling it.
‍

"LynxCare's hospital-based, federated approach responds to a growing need in life sciences research: quality-assured real-world evidence at scale, with patient data staying in the hospitals that hold it," says Sue Beecroft, Chair of the Board of LynxCare. "I look forward to working with the board and the team as the company expands across Europe."

About Holland Capital  Holland Capital has been investing in promising Dutch, Belgium and German companies with growth ambitions for over 40 years. The firm works closely with management teams to achieve sustainable growth and focuses on the Healthcare and Technology sectors through its specialized investment teams. Holland Capital has offices in Amsterdam and Düsseldorf.

Press contact Karen D'Haeseleer, Marketing & Communications